1. Enteric Fever (Salmonella Typhi and Salmonella Paratyphi), Chapter 30. pp:302-309. Essentials of Medical Microbiology, Third edition, Eds: Apurba S Sastry, Sandhya Bhat, 2021 by Jaypee
Brothers Medical Publishers.
2. Sastry AS, Bhat S. Salmonella and Enteric Fever. In: Essentials of Medical Microbiology. 3rd ed. Jaypee Brothers; 2021. Chapter 30, p. 302-309.
3. Ao TT, Feasey NA, Gordon MA, et al. Global burden of invasive nontyphoidal Salmonella disease. Emerg Infect Dis. 2015;21(6):941–949.
4. Chattaway MA, Langridge GC, Wain J. Salmonella nomenclature in the genomic era: A time for change. Sci Rep. 2021; 11:7494. Murray PR, Rosenthal KS, Pfaller MA. Enterobacteriaceae. In:
Medical Microbiology. 9th ed. Elsevier; 2021. Chapter 25, p. 257-270.
5. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive
Salmonella Infections. Clin Microbiol Rev. 2015;28(4):901-937.
6. Eng S-K, Pusparajah P, Ab Mutalib N-S, Ser H-L, Chan K-G, Lee L-H. Salmonella: A review on pathogenesis, epidemiology and antibiotic resistance. Front Life Sci. 2015;8(3):284–293.
7. Gal-Mor O, Boyle EC, Grassl GA. Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ. Front Microbiol. 2014;5:391.
8. Andino A, Hanning I. Salmonella enterica: survival, colonization, and virulence differences among serovars. ScientificWorldJournal. 2015;2015:520179.
9. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: A systematic analysis for the Global Burden of Disease
Study 2017. Lancet Infect Dis. 2019;19(4):369–81.
10. He Y, Wang J, Zhang R, Chen L, Zhang H, Qi X, et al. Epidemiology of foodborne diseases caused by Salmonella in Zhejiang Province, China, between 2010 and 2021. Front Public Health.
2023; 11:1127925.
11. WHO. Salmonella (non-typhoidal). World Health Organization. 2023. https://www.who.int/news-room/fact-sheets/detail/Salmonella-(non-typhoidal)
12. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of invasive nontyphoidal Salmonella disease. Emerg Infect Dis. 2015;21(6):941–9.
13. GBD 2017. Non-Typhoidal Salmonella Invasive Disease Collaborators. The global burden of non-typhoidal Salmonella invasive disease: a systematic analysis for the Global Burden of Disease
Study 2017. Lancet Infect Dis. 2019;19(12):1312-1324.
14. Enterobacteriaceae, Chapter 25. pp: 257-270. Medical Microbiology, 9th edition, Eds: Murray PR, Rosenthal KS, Pfaller MA, 2021 by Elsevier
15. Levine MM, Simon R. The gathering storm: Is untreatable typhoid fever on the way? mBio. 2018;9(2):e00482–18.
16. Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther. 2011;9(6):711–25.
17. MacLennan CA, Levine MM. Invasive nontyphoidal Salmonella disease in Africa: current status. Expert Rev Anti Infect Ther. 2013;11(5):443-446.
18. Pegues DA, Miller SI. Salmonella species, including Salmonella Typhi. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.
9th ed. Elsevier; 2020. Chapter 214.
19. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events.
Nat Genet. 2015;47(6):632-639.
20. Nair S, Ashton P, Doumith M, Connell S , Painset A , Mwaigwisya S, et al. WGS for surveillance of antimicrobial resistance. Microb Genom. 2016;2(9):e000064
21. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal Salmonellae. Curr Opin Infect Dis. 2008;21(5):531-538.
22. Post AS, Diallo SN, Guiraud I, Lompo P, Tahita MC, Maltha J, et al. Supporting evidence for the clinical impact of antimicrobial resistance in developing countries: Salmonella bloodstream
infections in Burkina Faso. BMC Infect Dis. 2020;20(1):35.
23. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid
encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018;9(1):e00105-18.
24. Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Phil.D, Pant D, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381(23):2209-2218.
25. Jin C, Gibani MM, Moore M, ∙ Juel HB, Jones E, Meiring J , et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled
human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10111):2472-2480.
26. Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid — Are conjugate vaccines arriving just in time? N Engl J Med. 2018;379(16):1493–5.
27. Ferrari RG, Rosario DKA, Cunha-Neto A, Mano SB, Figueiredo EES, Conte-Junior CA. Worldwide epidemiology of Salmonella serovars in animal-based foods: a meta-analysis. Appl Environ
Microbiol. 2019;85(14):e00591–19.
28. Gastrointestinal Infections due to Enterobacteriaceae : Diarrheagenic Escherichia coli, Shigellosis, Nontyphoidal Salmonellosis and Yersiniosis, Chapter 41. pp: 400-409. Essentials of Medical
Microbiology, Third edition, Eds: Apurba S Sastry, Sandhya Bhat, 2021 by Jaypee Brothers Medical Publishers
29. Gordon MA. Salmonella infections in immunocompromised adults. J Infect. 2008;56(6):413–22.
30. Worley MJ. Salmonella Bloodstream Infections. Trop Med Infect Dis. 2023;8(9):487.
31. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2022.
SHIGELLA
KAYNAKLAR
1. Gastrointestinal Infections due to Enterobacteriaceae: Diarrheagenic Escherichia coli, Shigellosis, Nontyphoidal Salmonellosis and Yersiniosis. In: Apurba S Sastry, Sandhya Bhat, eds. Essenti-
als of Medical Microbiology. Third edition, Jaypee Brothers Medical Publishers; 2021.
2. Enterobacteriaceae. In: Murray PR, Rosenthal KS, Pfaller MA, eds. Medical Microbiology. 9th edition, Elsevier; 2021.
3. Yassine I, Hansen EE, Lefèvre S, et al. ShigaPass: an in silico tool predicting Shigella serotypes from whole-genome sequencing assemblies. Microb Genom. 2023;9(3):000961.
4. Bajunaid W, Haidar-Ahmad N, Kottarampatel AH, et al. The T3SS of Shigella: expression, structure, function, and role in vacuole escape. Microorganisms. 2020;8(12):1933.
5. Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev. 2008;21(1):134–156.
6. Agaisse H. Molecular and Cellular Mechanisms of Shigella flexneri Dissemination. Front Cell Infect Microbiol. 2016; 6:29.
7. Zhu Z, Wang W, Cao M, et al. Virulence factors and molecular characteristics of Shigella flexneri isolated from calves with diarrhea. BMC Microbiol. 2021; 21:214.
8. Wang X, Yu D, Chui L, et al. A comprehensive review on Shiga toxin subtypes and their niche-related distribution characteristics in Shiga-toxin-producing E. coli and other bacterial hosts.
Microorganisms. 2024;12(4):687.
9. Nyarkoh R, Odoom A, Donkor ES. Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):1217.
10. Somda, N.S., Nyarkoh, R., Tankoano, A. et al. Molecular epidemiology of extended-spectrum beta-lactamases and carbapenemases-producing Shigella in Africa: a systematic review and
meta-analysis. BMC Infect Dis 25, 81 (2025).
11. European Centre for Disease Prevention and Control. Shigellosis: Annual Epidemiological Report for 2022. Stockholm, Sweden: ECDC; 2024. https://www.ecdc.europa.eu/sites/default/files/
documents/SHIG_AER_2022_Report.pdf
12. California Department of Public Health. CDPH Health Advisory: Rise in Extensively Drug-Resistant Shigella Strains – January to May 2024. Los Angeles County Public Health. Published
August 9, 2024.
13. Centers for Disease Control and Prevention. About Shigella Infection. Published January 10, 2024. https://www.cdc.gov/shigella/about/index.html
14. 14)Kotloff KL, Nataro JP, Blacklow NR, et al. Shigella Pathogenesis: New Insights through Advanced Methodologies. Microbiol Spectr. 2019;7(4).
15. UK Health Security Agency. Warning after rise in extremely drug-resistant Shigella. GOV.UK. Published December 21, 2023.
16. Centers for Disease Control and Prevention. Preventing Shigella Infection Among Young Children. Published April 2, 2024.
17. Public Health Agency of Canada. Shigella spp.: Infectious substances pathogen safety data sheet. Canada.ca. Published September 24, 2024.
18. Suspected triple outbreak of typhoid fever, shigellosis and cholera – Congo, https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON488
19. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet.2018;392(10142):1237-1248.
20. Centers for Disease Control and Prevention. Shigella (Shigellosis): Clinical Overview of Shigellosis. Updated 2024.
21. Ashida H, Ogawa M, Mimuro H, Sasakawa C. Shigella infection: a paradigm of enteric infection causing dysentery. Nat Rev Microbiol. 2015;13(12):623-635.
22. Centers for Disease Control and Prevention. Yellow Book 2024: Post-Travel Diarrhea.
23. Pourakbari B, Mamishi S, Kohan L, et al. Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. J Microbiol Immunol Infect. 2012;45(2):147-150.
24. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis.
2017;65(12):e45-e80.
25. U.S. Food and Drug Administration (FDA). Bacteriological Analytical Manual (BAM), Chapter 6: Shigella. Updated 2023.
26. UK Health Security Agency (UKHSA). UK Standards for Microbiology Investigations (UK SMI) ID 20: Identification of Shigella species. Issue 4.1; July 31, 2025.
27. UK Health Security Agency (UKHSA). UK SMI B 30: Investigation of faecal specimens for enteric pathogens. Updated 2024.
28. Centers for Disease Control and Prevention (CDC). Treatment of Shigella Infection. Updated 2024.
29. WHO. The selection and use of essential medicines. March, 2017.
30. Merck Manual Professional Edition. Shigellosis. Updated 2024.
31. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Bacterial Enteric Infections (Including Shigella). In: Guidelines for the Prevention and Treatment of Opportunistic Infe-
ctions in Adults and Adolescents with HIV. US Department of Health and Human Services; updated 2024.
32. CDC. Shigella Prevention & Control Toolkit. Centers for Disease Control and Prevention; March 19, 2024
33. MacLennan CA, Grow S, Ma LF, Steele AD. The Shigella vaccines pipeline. Vaccines (Basel). 2022;10(9):1376.
34. World Health Organization (WHO). Shigella: risk communication and community engagement guidance. WHO Regional Office for the Eastern Mediterranean. Published 2022.
35. World Health Organization (WHO). Shigella – Immunization, Vaccines and Biologicals. WHO; 2023.
36. Talaat KR, Alaimo C, Martin P, et al. Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection. eBioMedicine. 2021; 66:103310.
YERSINIA
KAYNAKLAR
1. Le Guern AS, Savin C, Angermeier H, et al. Yersinia artesiana sp. nov., Yersinia proxima sp. nov., Yersinia alsatica sp. nov., Yersina vastinensis sp. nov., Yersinia thracica sp. nov. and Yersinia
occitanica sp. nov., isolated from humans and animals. Int. J. Syst. Evol. Microbiol. 2020, 70, 5363–5372.
2. Enterobacteriaceae. In: Murray PR, Rosenthal KS, Pfaller MA, eds. Medical Microbiology. 9th edition, Elsevier; 2021.
3. Zoonotic Infections. In: Apurba S Sastry, Sandhya Bhat, eds. Essentials of Medical Microbiology. Third edition, Jaypee Brothers Medical Publishers; 2021.
4. Gastrointestinal Infections due to Enterobacteriaceae: Diarrheagenic Escherichia coli, Shigellosis, Nontyphoidal Salmonellosis and Yersiniosis. In: Apurba S Sastry, Sandhya Bhat, eds. Essenti-
als of Medical Microbiology. Third edition, Jaypee Brothers Medical Publishers; 2021.
5. Grygiel-Górniak, B. Current Challenges in Yersinia Diagnosis and Treatment. Microorganisms 2025, 13, 1133.
6. Somova LM, Antonenko FF, Timchenko, NF, Lyapun IN. Far Eastern Scarlet-Like Fever is a Special Clinical and Epidemic Manifestation of Yersinia pseudotuberculosis Infection in Russia.
Pathogens 2020, 9, 436.
7. Savin C, Le Guern AS, Chereau F et al. First Description of a Yersinia pseudotuberculosis Clonal Outbreak in France, Confirmed Using a New Core Genome Multilocus Sequence Typing
Method. Microbiol. Spectr. 2022, 10, e01145-22.
8. Kaasch AJ, Dinter J, Goeser T, Plum G, Seifert H. Yersinia pseudotuberculosis bloodstream infection and septic arthritis: Case report and review of the literature. Infection 2012, 40, 185–190.
9. Galindo, C.L.; Rosenzweig, J.A.; Kirtley, M.L.; Chopra, A.K. Pathogenesis of Y. enterocolitica and Y. pseudotuberculosis in Human Yersiniosis. J. Pathog. 2011, 2011, 182051.
10. European Food Safety Authority (EFSA). European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2023 Zoonoses report. EFSA J. 2024, 22, e9106.
11. Bottone EJ. Yersinia enterocolitica: Overview and epidemiologic correlates. Microbes Infect. 1999, 1, 323–333.
12. Eurosurveillance-Editorial-Team. The 2013 joint ECDC/EFSA report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks published. Eurosurveillance 2015, 20, 6.
13. EFSA. ECDC The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2015. EFSA J. 2016.
14. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States–major pathogens. Emerg. Infect. Dis. 2011, 17, 7–15.
15. Prevention Centers for Disease Control and Yersinia enterocolitica (Yersiniosis). 2016. Available online: https://www.cdc.gov/yersinia/
16. Nesbakken, T. Surveillance and Control of Enteric Yersinioses. In Yersinia: System Biology and Control; Carniel, E., Hinnebusch, B.J., Eds.; Caister Academic Press: Norfolk, UK, 2012; pp. 217–238.
17. Amphlett A. Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A. Open Forum
Infect. Dis. 2015, 3, ofv202.
18. Suzuki S, Suzuki K, Furukawa T, Nakajima M, Sakai H. Past Endemic Izumi Fever or Yersinia pseudotuberculosis Infection Reappears Sporadically. Intern. Med. 2024, 63, 1317–1322.
19. Savin C, Leclercq A, Carniel E. Evaluation of a single procedure allowing the isolation of enteropathogenic Yersinia along with other bacterial enteropathogens from human stools. PLoS ONE
2012, 7, e41176.
20. Binnicker MJ. Multiplex Molecular Panels for Diagnosis of Gastrointestinal Infection: Performance, Result Interpretation, and Cost-Effectiveness. J. Clin. Microbiol. 2015, 53, 3723–3728.
21. Freeman CN, Mehta N, Rabari J, Kosar J, Blondeau JM, Hamula CL. Retrospective analysis and clinical performance of BD MAX enteric pathogen testing with a focus on reliable identification
of vibrio species in stool samples. Diagn. Microbiol. Infect.Dis. 2025, 111, 116715.
22. Bonardi S, Alpigiani I, Pongolini S, et.al. Detection, enumeration and characterization of Yersinia enterocolitica 4/O:3 in pig tonsils at slaughter in Northern Italy. Int. J. Food Microbiol. 2014,
177, 9–15.
23. Demeure CE, Dussurget O, Mas Fiol G, Le Guern AS, Savin C, Pizarro-Cerdá J. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vacci-
nation, and diagnostics. Genes Immun. 2019, 20, 357-370.
24. Triantafillidis JK, Thomaidis T, Papalois A. Terminal Ileitis due to Yersinia Infection: An Underdiagnosed Situation. Biomed. Res. Int. 2020, 2020, 1240626.
25. Spyropoulos C. Selective immunoglobulin M deficiency and terminal ileitis due to Yersinia enterocolitica infection: A clinically interesting coexistence. Gastroenterol. Hepatol. Open Access
2015, 2, 00036.
26. Montenegro L, Piscitelli D, Giorgio F, et al. Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease. World J. Gastroenterol. 2014, 20, 17686–17689.
27. Biagi F, Bianchi PI, Zilli A, et al. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: A clinical and histopathologic study. Am. J. Clin. Pathol.
2012, 138, 185–189.
28. Yel L. Selective IgA Deficiency. J. Clin. Immunol. 2010, 30, 10–16.
29. Vo Ngoc DTL, Krist L, van Overveld FJ, Rijkers GT. The Long and Winding Road to IgA Deficiency: Causes and Consequences. Expert. Rev. Clin. Immunol. 2017, 13, 371–382.
30. Zhang J, van Oostrom D, Li J, Savelkoul HFJ. Innate Mechanisms in Selective IgA Deficiency. Front. Immunol. 2021, 12, 649112.
31. Rastawicki W, Jakubczak A. Serum immunoglobulin IgG subclass distribution of antibody responses to Yop proteins and lipopolysaccharide of Yersinia enterocolitica in patients with yersini-
osis. Pol. J. Microbiol. 2007, 56, 233–238.
32. Wunderink HF, Oostvogel PM, Frenay IH, Notermans DW, Fruth A, Kuijper EJ. Difficulties in diagnosing terminal ileitis due to Yersinia pseudotuberculosis. Eur. J. Clin. Microbiol. Infect. Dis.
2014, 33, 197–200.
33. Bui TH, Ikeuchi S, O’Brien YS, et al. Multiplex PCR method for differentiating highly pathogenic Yersinia enterocolitica and low pathogenic Yersinia enterocolitica, and Yersinia pseudotuber-
culosis. J. Vet. Med. Sci. 2021, 83, 1982–1987.
34. Stevens MJA, Barmettler K, Kelbert L, Stephan R, Nuesch-Inderbinen M. Genome based characterization of Yersinia enterocolitica from different food matrices in Switzerland in 2024. Infect.
Genet. Evol. 2025, 128, 105719.
35. Brusa V, Costa M, Oteiza JM, et al. Prioritization of vegetable-borne biological hazards in Argentina using a multicriteria decision analysis tool. Food Sci. Technol. Int. 2024, 30, 680–696.
36. Gravemann U, Handke W, Schulze TJ, Seltsam A. Growth and Distribution of Bacteria in Contaminated Whole Blood and Derived Blood Components. Transfus. Med. Hemother. 2024, 51, 76–83.
37. Wu F, Ren F, Xie X, Meng J, Wu X. The implication of viability and pathogenicity by truncated lipopolysaccharide in Yersinia enterocolitica. Appl. Microbiol. Biotechnol. 2023, 107, 7165–7180.
38. Guarino A Albano F Ashkenazi S, et al. The ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert Working Group.
European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute
gastroenteritis in children in Europe: Executive summary. J. Pediatr. Gastroenterol. Nutr. 2008, 46, 619–621.
39. Fàbrega A, Balleste-Delpierre C, Vila J. Antimicrobial resistance in Yersinia enterocolitica. Antimicrob. Resist. Food Saf. Methods Tech. 2015, 9, 77–104.
40. Sotohy SA, Diab MS, Ewida RM, Aballah A, Eldin NKA. An investigative study on Yersinia enterocolitica in animals, humans and dried milk in New Valley Governorate, Egypt. BMC Micro-
biol. 2024, 24, 395.